ClinicalTrials.gg
CompletedNCT05105308Updated Feb 17, 2026

Chompions! A Treatment Study for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID)

An interventional study of Family Assisted Diet (FAD) and Feeling and Body Investigator_ARFID Division (FBI-ARFID) in ARFID, Picky Eating and Eating Disorders in Children, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 60 Months to 119 Months. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
60 Months to 119 Months
Sex
All
01

Study summary

Avoidant Restrictive Food Intake Disorder (ARFID) is a disorder that affects toddlers, children, adolescents, and adults. Individuals with ARFID are not able to consume an adequate amount or variety of food to a degree that it affects their mental and/or physical health. ARFID often begins in early childhood so it is important to treat children in early in life as possible to prevent any negative consequences of poor nutrition. There are currently no treatments for young children with ARFID. The investigators have developed two different study programs and the purpose of this study is to test them out and see if they help children with ARFID and to learn more about how these study programs work.

02

Conditions studied

  • ARFID
  • Picky Eating
  • Eating Disorders in Children

Keywords

  • FBI-ARFID
  • Eating Disorder
  • Avoidant Restrictive Food Intake Disorder
  • Food Neophobia
  • Treatment for Children
  • Sensory Sensitivity
  • Picky Eating
  • Low Weight
  • Nutritional Deficiencies
03

In context

Avoidant Restrictive Food Intake Disorder

40 studies on the registry are indexed under Avoidant Restrictive Food Intake Disorder; 12 are open to participants now.

This study's enrollment of 203 is above the median of 38 across 28 interventional studies indexed under Avoidant Restrictive Food Intake Disorder.

Browse Avoidant Restrictive Food Intake Disorder studies →

Lead sponsor

Duke University is the lead sponsor of 2,063 studies on the registry; 273 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Months to 119 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child is between 60 and 119 months (5 years and up to 9 years, 11 months)
  • English Speaking
  • Consent given by parent and assent by child

And any one or more of the following:

  • Score of 29 or above on the Child Food Neophobia Scale
  • Underweight
  • Current diagnosis of ARFID
  • Dependent on nutritional supplements to achieve sufficient calories for optimal growth
  • Avoiding activities due to eating rated at least almost always

Exclusion criteria

Exclusion Criteria:

  • Child is known to have a severe intellectual disability based on medical chart review
  • Meets diagnostic criteria for anorexia nervosa or bulimia nervosa
  • Is currently enrolled in a treatment study or receiving active treatment for ARFID
  • Taking medications known to affect appetite
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
203 participants (actual)

Study arms

  • Active comparator
    Family Assisted Diet (FAD)

    This is a 20-session intervention with a child and the child's parents that consists of helping parents set goals around their child's renourishment; consider barriers to implementing proposed plans; thinking through strategies to avoid barriers; and providing ongoing support for plan implementation.

    Behavioral: Family Assisted Diet (FAD)

  • Experimental
    Feeling and Body Investigator_ARFID Division (FBI-ARFID)

    This is a 20-session intervention with a child and the child's parents that consists of 4 components: 1) psychoeducation of somatic body sensations and sensory features of foods using playful characters (e.g., Aftertaste Anthony); 2) in-session exercises that expose family members to different body and food sensations so they can learn something new about their body and food; 3) body brainstorm worksheets that help them generalize what they learn in session to outside of treatment; and 4) Decision-tree practice worksheets that help them map body sensations to meanings and actions and to track explorations with food.

    Behavioral: Feeling and Body Investigator_ARFID Division (FBI-ARFID)

Interventions

  • BehavioralFamily Assisted Diet (FAD)

    A behavioral intervention consisting of helping parents renourish their child and conduct food exposures with new foods.

    Also known as: FAD

  • BehavioralFeeling and Body Investigator_ARFID Division (FBI-ARFID)

    A sensory and somatic focused intervention that educates children about feelings and bodily sensations, in-session exposures to body and food sensations, different strategies to improve generalization while at home, and strategies to help them understand and track experiences exploring food.

    Also known as: FBI-ARFID

06

What researchers measure

Primary outcomes

  1. Change in the number of clinically severe symptoms of Avoidant Restrictive Food Intake Disorder (ARFID) as measured by the PARDI (Pica, ARFID, and Rumination Diagnostic Interview)

    The 17-item PARDI measures symptoms including body mass index, diet quality, dependence on supplement use for sufficient calories, and psychosocial impairment. Each item assesses a symptom on a 0 - 6 scale, with scores above 4 indicating that it is a clinically severe symptom.

    Time frame: Baseline, Post-Treatment (up to 30 weeks), 3-Months Post-Treatment

Secondary outcomes

  1. Nutrition Quantity as measured by 3-day 24-hour dietary recalls

    Nutrition Quantity is measured by two weekdays and one weekend day assisted dietary recall with the parent of the child. Using the Harris-Benedict equation to determine a child's nutritional needs, the following will be measured: 1) Child unable to meet daily energy requirements without supplement and/or 2) Child's dietary intake is below energy needs on all 3 days.

    Time frame: Baseline

  2. Nutrition Quantity as measured by 3-day 24-hour dietary recalls

    Nutrition Quantity is measured by two weekdays and one weekend day assisted dietary recall with the parent of the child. Using the Harris-Benedict equation to determine a child's nutritional needs, the following outcomes will be measured: 1) Child unable to meet daily energy requirements without supplement and/or 2) Child's dietary intake is below energy needs on all 3 days.

    Time frame: Post-Treatment (up to 30 weeks)

  3. Psychosocial Functioning as measured by items on the PARDI

    Psychosocial functioning is measured by items on the PARDI indicating that the child does not avoid social events due to eating/food and less than or equal to 1 indicating that the child is able to remain at the table and demonstrate age-appropriate behaviors.

    Time frame: Baseline

  4. Psychosocial Functioning as measured by items on the PARDI

    Psychosocial functioning is measured by items on the PARDI indicating that the child does not avoid social events due to eating/food and less than or equal to 1 indicating that the child is able to remain at the table and demonstrate age-appropriate behaviors.

    Time frame: Post-Treatment (up to 30 weeks)

  5. Psychosocial Functioning as measured by items on the PARDI

    Psychosocial functioning is measured by items on the PARDI indicating that the child does not avoid social events due to eating/food and less than or equal to 1 indicating that the child is able to remain at the table and demonstrate age-appropriate behaviors.

    Time frame: 3-Months Post-Treatment

  6. Nutrition Quality as measured by 3-day 24-hour dietary recalls

    Nutrition Quality is measured by the average macronutrient and micronutrient assessment from two weekdays and one weekend day assisted dietary recall with the parent of the child.

    Time frame: Baseline

  7. Nutrition Quality as measured by 3-day 24-hour dietary recalls

    Nutrition Quality is measured by the average macronutrient and micronutrient assessment from two weekdays and one weekend day assisted dietary recall with the parent of the child.

    Time frame: Post-Treatment (up to 30 weeks)

  8. Body Mass Index (BMI) as measured by height and weight

    BMI will be measured by parents at home with scales and tape measures provided to them.

    Time frame: Baseline

  9. Body Mass Index (BMI) as measured by height and weight

    BMI will be measured by parents at home with scales and tape measures provided to them.

    Time frame: Weekly (up to 30 weeks)

  10. Body Mass Index (BMI) as measured by height and weight

    BMI will be measured by parents at home with scales and tape measures provided to them.

    Time frame: Post-Treatment (up to 30 weeks)

  11. Body Mass Index (BMI) as measured by height and weight

    BMI will be measured by parents at home with scales and tape measures provided to them.

    Time frame: 3-Months Post-Treatment

07

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
08

References and documents

Publications

  • Zucker N, Mauro C, Craske M, Wagner HR, Datta N, Hopkins H, Caldwell K, Kiridly A, Marsan S, Maslow G, Mayer E, Egger H. Acceptance-based interoceptive exposure for young children with functional abdominal pain. Behav Res Ther. 2017 Oct;97:200-212. doi: 10.1016/j.brat.2017.07.009. Epub 2017 Jul 29. PubMed 28826066 ↗
  • Zucker NL, LaVia MC, Craske MG, Foukal M, Harris AA, Datta N, Savereide E, Maslow GR. Feeling and body investigators (FBI): ARFID division-An acceptance-based interoceptive exposure treatment for children with ARFID. Int J Eat Disord. 2019 Apr;52(4):466-472. doi: 10.1002/eat.22996. Epub 2018 Dec 31. PubMed 30597590 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Sep 2025, 43 months.

Of 17 interventional studies with no phase under Avoidant Restrictive Food Intake Disorder, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Nov 3, 2021
StartActual
Feb 10, 2022
Primary completionActual
Sep 29, 2025
CompletionActual
Sep 29, 2025
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05105308
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Feb 10, 2022
Primary completion
Sep 29, 2025
Completion
Sep 29, 2025
Last update
Feb 17, 2026

Study contacts

Nancy L Zucker, PhD
principal investigator · Duke University
Guillermo Sapiro, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion